SLC5A2 and congestive heart failure: A remarkable decline was observed in heart failure hospitalizations (HFH) and mortality in CHF.7 A randomized clinical trial on dapagliflozin showed substantial decrease in HF events after introduction of the drug in CHF patients having reduced ejection fraction (EF) irrespective of their diabetic status.8 Despite favorable results in CHF, the efficiency of SGLT2 inhibitors in AHF still needs to be investigated.